Emergex Vaccines Holding Limited (“Emergex”), a UK-based biotechnology company headquartered in Oxford, is pioneering a new approach to vaccine development in order to address some of the world’s most immediate health threats including Flaviviruses, such as Dengue Fever and Zika, as well as Filoviruses, such as Ebola and Marburg viruses, and seasonal and pandemic influenza.